Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IVIg plus prednisone vs high-dose dexamethasone for adult ITP with bleeding (IVIORDEX)
2024-516403-16-00Phase 3Authorised
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Nov 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised trial in immune thrombocytopenia (ITP) comparing IVIg plus oral prednisone with IVIg plus high-dose dexamethasone (Neofordex) (2 arms). Primary endpoint: Time to initial platelet response within 5 days. Planned start Nov 2024; status: authorised.
02
Drugs
dexamethasoneprednisoneimmune globulin
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on 2024-516403-16-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516403-16-00.